InMed’s President and CEO, Eric A. Adams, presents at Renmark Financial’s Virtual Non-Deal Roadshow on February 26, 2026.
In the presentation and Q&A, Mr. Adams gives an overview of the company’s pharmaceutical programs, including lead drug candidate INM-901 for Alzheimer’s disease and the upcoming development plans for the program.
He answers the following questions about the company’s INM-901 Alzheimer’s disease drug candidate:
- Will a Phase 1 clinical trial of INM-901 be conducted in healthy volunteers or in patients living with Alzheimer’s disease?
- As INM-901 moves into the clinical development phase, do you expect to increase headcount or will this be outsourced?
- How soon do you expect to start INM-901 Phase 1 clinical trial enrollment following a successful IND application?
- While you’ve had promising preclinical data of INM-901 so far, what gives you the confidence INM-901’s preclinical results will translate similarly into human clinical trials?
